Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05122546
Title CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

renal cell carcinoma


Cabozantinib + Nivolumab

Cabozantinib + CBM588 + Nivolumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.